Investigational Drug Shows Potentialin Phase 3 Obesity Trial - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

  • By

  • Andrea Surnit

  • June 10, 2026

  • 4 min

Share

Original Source(s)

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

  • by Andrea Surnit

  • June 10, 2026

Related Content

Ovulation may shift preferences toward conspicuous luxury

Across 3 studies, higher fertility was associated with greater preference for luxury when it was visible, personally relevant, and potentially noticeable to others.

Estriol may ease menopause-related cognitive decline

Women reported improvement across 6 cognitive domains during 12 months of estriol-based treatment, while murine models suggested a potential astrocyte-mediated mechanism.

Metabolic Improvements and Weight Trajectories After Metabolic-Bariatric Surgery in Women with Polyendocrine Metabolic Ovarian Syndrome